RE: Someone maths is wrong30 Oct 2020 08:53
Exactly casper, this share is worth just alone rms stake, I like this rapid test
Advance Energy #ADV are actively tracking oil & gas deals - expect an announcement 'within months'Watch Now
Share PricesBraveheart Inv Share PriceBraveheart Inv Regulatory NewsFurther update re Paraytec LimitedBraveheart Inv Regulatory News (BRH)BRH Share
PriceBRH Share
NewsBRH Share
Chat2BRH Share
Trades92BRH
Live RNS
BRH Information
Buy BRH SharesAdd BRH to WatchlistAdd BRH to AlertAdd BRH to myTerminal
Share Price Information for Braveheart Inv (BRH)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:50.00
Bid:49.00
Ask:51.00
Change:-3.00 (-5.66%)
Spread: 2.00 (4.00%)
Open: 54.50
High: 55.00
Low: 49.40
Yest. Close: 53.00
Last checked at 08:51:33
SPONSORED BY EXAMSOFTLeicester Medical School Goes Digital
SEE MORE
Further update re Paraytec Limited
Fri, 16th Oct 2020 07:00
RNS Number : 2711C
Braveheart Investment Group plc
16 October 2020
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
16 October 2020
Braveheart Investment Group plc
("Braveheart" or the "Group")
Further update re Paraytec Limited
Braveheart Investment Group (AIM: BRH), is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.
As announced on 5 October 2020, proof of concept was achieved for the Optical Detection System. Since then the focus of the Proof of Concept trials have has been on the Capture & Signal Generation Modules.
Braveheart is now pleased to confirm that Proof of Concept has now been achieved for the Capture & Signal Generation Modules, which successfully completes the Proof of Concept trials. The directors of Braveheart believe that this test will be the first to combine a rapid result with very high detection sensitivity. Work will now turn toward the acquisition of clinically relevant data, to facilitate optimisation of the functional capabilities of the test, together with a programme of product refinement and development. Meanwhile, regulatory approval for live virus trials and the acquisition of clinical data is being sought.
Trevor Brown, CEO Braveheart Investment Group, commented "This is a phenomenal achievement for all concerned. The inspirational leadership and innovative brilliance of Professor Carl Smythe and his talented team have resulted in proof of concept in a little over four months"
Sign In
Follow the stocks
